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Carotenoid as a Potential Antioxidant Marker for Schizophrenia
(Karotenoid Berpotensi sebagai Penanda Antioksidan bagi Skizofrenia)
T. J. CHOW & H.C. LOH*
ABSTRACT
 Free radicals are results of aerobic activities and can damage cells when present in excess by causing oxidative stress. 
Antioxidants efficiently quench free radicals to counteract oxidative stress. Carotenoids are antioxidants that have 
detectable natural colorant which can be measured as indicator of antioxidant level in human. The aim of this study is to 
investigate possible association of carotenoid antioxidant levels in schizophrenia. A total of 524 patients with schizophrenia 
from Hospital Bahagia Ulu Kinta, Malaysia and 391 healthy controls were recruited. Subjects’ skin carotenoid levels were 
measured through a non-invasive approach using Raman spectroscopy. Patients with schizophrenia showed significant 
(p < 0.01) lower carotenoid level compared to healthy controls. Factors such as gender, age, subtypes, antipsychotic 
drug treatments, and duration of illness did not differ significantly among patients. It is concluded that patient with 
schizophrenia have low levels of carotenoid antioxidants and is suggested to experience higher level of oxidative stress 
compared to healthy individuals. 
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ABSTRAK
Radikal bebas merupakan hasilan daripada aktiviti aerobick dan boleh merosakkan sel melalui tekanan oksidatif apabila 
hadir secara berlebihan.  Antioksidan menghilangkan radikal bebas untuk mengatasi tekanan oksidatif secara berkesan. 
Antioksidan karotenoid adalah pewarna semula jadi yang dapat dikesan serta diukur sebagai penanda aras antioksida 
dalam manusia. Matlamat kajian ini adalah untuk menyiasat kemungkinan wujudnya hubungan paras antioksida 
karotenoid dalam skizofrenia. Sejumlah 524 pesakit skizofrenia dari Hospital Bahagia Ulu Kinta, Malaysia dan 391 
kawalan yang sihat direkrut.  Aras karotenoid di kulit subjek diukur melalui spektroskopi Raman yang “tidak-invasif”. 
Pesakit skizofrenia menunjukkan paras karotenoid yang rendah secara nyata (P > 0.01) berbanding dengan kawalan 
sihat. Faktor-faktor seperti jantina, umur, sub-jenis, rawatan ubat antipsikotik dan tempoh sakit adalah tidak signifikan di 
kalangan pesakit. Secara kesimpulannya, pesakit skizofrenia mempunyai aras antioksidan karotenoid yang lebih rendah 
dan dicadangkan mengalami paras tekanan oksidatif yang lebih tinggi berbanding dengan individu yang sihat.
Kata kunci: Antioksidan; karotenoid; tekanan oksidatif
INTRODUCTION
Schizophrenia (SCZ) is a major psychiatric disorder that 
alters an individual’s perception, thought, mood and 
behavior (Malaysian Psychiatric Association 2009). It 
affects 1 % of the world population and each individual has 
0.7 % risk of developing the disorder over lifetime (Bilder 
2006; Tandon et al. 2008). There are variations in the 
incidence of SCZ, where family history, urban-living and 
oxidative stress are linked to a higher risk for developing 
the disorder (Othmen et al. 2008; Tsuboi et al. 2006).
 Free radicals are reactive oxygen species reported to 
play a major role in the aetiology of many diseases such 
as diabetes (Webb & Falkowski 2009), neuropsychiatric 
disorder (Bilici et al. 2001), SCZ (Othmen et al. 2008) and 
many age-related diseases. They are usually produced 
as the body immune response to exogenous oxidants for 
instance, cigarette smoke, inappropriate diet and radiation 
(Packer 2006). Free radicals seek to damage cellular 
components such as lipid, which is essential in nerve cell 
membrane function and would affect signal transmissions 
and might degenerate brain functions (Block 1999). 
 Antioxidants serve to counteract oxidative stress, 
improving immune functions and prevent diseases (Surh 
& Packer 2005). Examples of antioxidants in human 
plasma and tissue are vitamin A, vitamin C, vitamin E, 
and the carotenoids (Nishino et al.  2002). Amongst them, 
carotenoids are unique in their natural colorants that 
are distributed in human tissue and can be detected as 
certain wavelengths when they are stimulated (Khachik 
et al. 1999). Carotenoids not only inhibit free radicals, 
they are also efficient quenchers of the cancer-causing 
singlet oxygen. Important sources of carotenoid include: 
red, orange, yellow, and green vegetable and fruits (Stahl 
& Sies 1999). Skin carotenoid has been reported as a 
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reliable indicator of overall antioxidant level in human 
that provides evidence of oxidative stress which is often 
related to diseases (Svilaas et al. 2004). 
 Factors such as lifestyle, dietary habit and smoking 
habit affect individual antioxidant level. Deteriorating 
lifestyle factors such as excessive emotional stress, 
alcohol and drug abuse induce free radicals production in 
human brain (Hiramatsu 2006; Tsuboi et al. 2006). Diet 
heavy on fats with considerable less fruits and vegetables 
would result in low antioxidant level due the presence of 
polyunsaturated fats in most fried and overcooked food 
that would react with free radicals in a chain reaction, 
exhausting the antioxidants and intensifying oxidative 
damage (Hiramatsu 2006). Similarly, antioxidant level in 
blood and tissue of smokers tends to be lower than non-
smokers. Combustion of the tar component in cigarettes 
actively reduced oxygen to hydrogen peroxide, causing 
oxidative stress (Duthie 1999). Smoking psychiatric 
patients develop more psychotic symptoms and require 
higher dose of antipsychotics compared to non-smoking 
patients (Diehl et al. 2009).
 Most antioxidant studies on diseases were done 
by measuring enzyme activity in red blood cell and 
plasma using high-performance liquid chromatography 
techniques. However, such methods are invasive, 
expensive and impractical for a large sample size. In the 
present study, total antioxidant level was determined by 
a simple, rapid, and non-invasive technique using Raman 
spectroscopy which utilises laser spectroscopic technique 
to detect characteristic vibration energy of carotenoids 
on human skin (Hata et al. 2000). Although Othmen et 
al. (2008) argued that peripheral markers may not reflect 
similar changes in the central nervous system, research 
demonstrated a significant correlation between serum 
carotenoid and skin carotenoid levels (Zidichouski et al. 
2004), attributing the Raman spectroscopy method to be 
more specific, sensitive, cost effective and reproducible. 
Thus, antioxidant detection using Raman spectroscopy has 
been applied in illnesses such as cancer, cardiovascular 
disease (Smidt 2005) and eye disease (Zhao et al. 2003). 
This study examined possible differences of skin carotenoid 
level in relation to demographic and clinical characteristics 
between SCZ and healthy population. 
MATERIALS AND METHODS
SUBJECT SELECTION
The sample population consisted of 524 SCZ subjects 
recruited from Ulu Kinta Psychiatric Hospital (HBUK), 
Perak, Malaysia and 391 healthy control subjects in the 
study period from February 2008 until December 2009. 
Socio-demographic data (age and gender) and other 
relevant clinical information (duration of illness, subtypes 
of SCZ and medications used) were collected. The 380 male 
and 144 female patients were grouped into their respective 
subtype: catatonic (n = 4), disorganised (n = 96), paranoid 
(n = 217), residual (n = 8), and undifferentiated (n = 199). 
The diagnoses of SCZ subjects were done according to the 
Mini International Neuropsychiatric Interview (M.I.N.I.), 
English version 5.0.0 (Sheehan et al. 1998). 
 The 391 healthy control subjects (male = 183, female 
= 208) were selected based on the following exclusion 
criteria: (1) no personal history of mental disorders, (2) no 
family history of mental disorders, (3) no history of major 
illness such as cancer and AIDS, (4) not on drug therapy or 
substance abuse and lastly (5) non-smoker. Dietary fruits 
and vegetables intakes of controls were ascertained. Only 
those who had two to three servings of fruits and vegetables 
intake per day, matching the diet of patients, were recruited 
in this study. Due to smoking restriction in HBUK, and 
population compatibility, only non-smoking controls were 
recruited. 
 Both patients and controls were residents of Malaysia, 
with age ranging from 16 to 80 years (patient mean age = 
44.95 ± 12.50; control mean age = 32.82 ± 11.76). Written 
consents were obtained from subjects before participation 
in the study. This study was approved by the Medical 
Research & Ethics Committee (MREC), Ministry of Health 
(MoH), Malaysia (KKM/NIHSEC/08/0804/P07-42).
MEASUREMENT OF CAROTENOID LEvEL
Carotenoid levels of subjects were measured using 
Pharmanex® BioPhotonic Scanner S2 (Pharmanex, Provo, 
U.S.A.). Subjects were required to wash and dry their 
palms prior to the measurement and place the palm on the 
Scanner (in front of the Raman laser) for two minutes. 
Individual skin carotenoid was recorded and compiled 
for analysis. Score were categorised into five ranges: the 
lowest range below 20,000; followed by value ranging 
from 20,001 to 30,000; 30,001 to 40,000; 40,001 to 50,000; 
and lastly, the highest range of 50,001 to 60,000.
vALIDATION By FRAP ASSAy
As a validation to the skin carotenoid level obtained using 
Raman spectroscopy, Ferric Reducing Ability of Plasma 
(FRAP) assay was performed on 87 patients and 70 controls 
that were randomly chosen from the main study group. 
This assay is based on the reduction of ferric (III) to 
ferrous (II) through antioxidants. Using a modified method 
adapted from Benzie and Strain (1996), total antioxidant 
level of the serum samples were determined using FRAP 
assay. Fresh FRAP solution were mixed with serum samples 
and incubated for 10 min in dark before measurement of 
absorbance at 593 nm.
STATISTICAL ANALySIS
Data analyses were perform using Statistical Package 
for Social Sciences (SPSS) version 16.0 for Windows 
(SPSS Inc, Chicago, USA). Carotenoid score differences 
between SCZ and control subjects were evaluated using 
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independent sample T-test. variables tested using one-way 
analysis of variance (ANOvA) included gender, age, SCZ 
subtypes, patient medication, depot injection and duration 
of illness. 
 In the analysis of SCZ subtype, subjects with catatonic 
and residual subtype were excluded from the analysis 
due to low sample size. Both controls and patients were 
grouped into four age ranges: 16 to 30 years, 31 to 40 
years, 41 to 50 years and more than 50 years of age. For the 
analysis of medication consumption, patients were divided 
into three categories depending on their medication: typical 
antipsychotics such as haloperidol and chlorpromazine; 
atypical antipsychotics such as olanzapine and clozapine; 
and other psychotropics that are not in the above two 
categories, such as diazepam and fluvoxamine. Further 
analysis of depot injection compared patients that received 
intramuscular injection of antipsychotics with patients that 
did not receive any injections. In the analysis of duration of 
illness, patients were grouped into four duration periods: 
ill for less than 5 years, between 5 and 10 years, between 
10 and 20 years and above 20 years. 
 For each studied population, Levene’s homogeneity 
test was used to test for equality variances. Descriptive 
statistics were calculated for all variables and mean score 
and standard deviation (SD) was reported separately 
for each variable. p-value of < 0.01 was considered as 
significant.
 The correlation between carotenoid level measured by 
FRAP assay and Raman spectroscopy was evaluated using 
Pearson’s correlation test, where r-value nearer to 1 was 
considered as a significant correlation.
RESULTS
Each population in our study was homogenous for the 
equality of variances. Among the SCZ patients, 84 % 
obtained carotenoid scores less than 30,000. In contrast, 
33 % of controls scored higher than 30,000. Significant (p 
< 0.01) lower carotenoid score was observed in patients 
compared to controls. Mean carotenoid score of controls 
and patients were 27,200 ± 7675 and 22,213 ± 8774 
respectively, showing 18% difference. On average, female 
obtained significantly (p < 0.01) higher mean carotenoid 
score compared to male (Table 1). Mean scores for 
females in the control and patient group were 15 % and 
17 % significantly (P < 0.01) higher than that of males 
respectively.
 The mean carotenoid scores with respect to different 
age ranges are summarised in Table 1. We studied mean 
carotenoid score between patients and controls (1) within 
individual age range and (2) between different age ranges. 
Comparison between controls and patients in different age 
range showed no statistical significance, but on average, 
controls’ mean score were 14.7 % higher than patients. 
 In subtype analysis (Figure 1), carotenoid levels for 
disorganised (mean = 22,106 ± 6975), paranoid (mean = 
21,715 ± 7984), and undifferentiated (mean = 22,585 ± 
7735) subtypes were not significantly different from each 
other. On the other hand, mean carotenoid score of patients 
with atypical antipsychotics treatment were found to be 
higher (mean = 23,045 ± 7727) compared to those typical 
antipsychotics treatment (mean = 22,119 ± 7898) and 
other psychotropic medications (mean = 21,430 ± 7098). 
ANOvA did not show significant difference in mean score 
and medications among patients. Similarly, depot injection 
and duration of illness did not show significant difference 
with carotenoid score.
 For the FRAP validation assay, the correlation between 
carotenoid level evaluated by FRAP assay and Raman 
spectroscopy measurement was determined. The relationship 
was established as equation of y = 0.024x (R2 = 0.688) 
for controls (Figure 2), and y = 0.027x (R2 = 0.562) for 
patients (Figure 3). Analysis of Pearson’s correlation 
showed significant strong positive correlation between FRAP 
antioxidant level and skin carotenoid level in controls (r = 
0.830, p < 0.01) and patients (r = 0.811, p < 0.01). 
TABLE 1. Mean carotenoid score for demographic characteristics of subjects
Characteristics Mean Carotenoid Score ± SD
 n Control n Patient P-value
Gender
Male 183 25,257 ± 8571 380 21,540 ± 7434 < 0.01
Female 208 28,865 ± 8814 144 23,990 ± 8030 < 0.01
P-value < 0.01 < 0.01
Age
16-30 years 209 25,406 ± 7286 65 23,364 ± 9045 > 0.01
31-40 years 70 28,418 ± 8322 147 22,662 ± 8067 > 0.01
41-50 years 54 28,706 ± 9882 144 22,402 ± 7324 > 0.01
 >50 years 49 29,285 ± 1,1245 178 22,247 ± 7965 > 0.01
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FIGURE 1. Mean carotenoid score for clinical characteristics of patients. 
Number of patients (n) is stated in brackets
FIGURE 2. Relationship between FRAP antioxidant level with control
skin carotenoid level
FIGURE 3. Relationship between FRAP antioxidant level with 







The total antioxidant level evaluated by FRAP assay 
correlates with carotenoid level measured by Raman 
spectroscopy. Results showed the trend of increasing serum 
antioxidant level with increasing skin carotenoid level. 
This positive correlation trend emphasised that carotenoid 
correspond to the total antioxidant capacity human serum 
(Svilaas et al. 2004).
 The main findings of the present study are that (1) 
SCZ was characterised by significantly (p < 0.01) lower 
carotenoid level compared to controls; and (2) the possibility 
of treatment with antipsychotics as the main factor for the 
reduced antioxidant levels shown in patients. Recent studies 
on plasma antioxidant in SCZ patients showed similar trend 
of reduced antioxidant level that is associated to high 
oxidative stress (Kunz et al. 2008; Reddy et al. 2003). 
However, it is important to investigate whether this trend 
applies solely to certain SCZ subtypes. Gama et al. (2008) 
reported no effect of different subtypes on antioxidant level. 
Similarly, our study observed that carotenoid level did not 
significantly associate with subtypes in the patient group, 
and thus suggested that subtype differentiation has no or 
equal effect on oxidative damage. 
 Both control and patient female have significantly 
higher carotenoid score than males suggesting that gender 
is not an affecting factor in SCZ. Rather, the association 
between plasma antioxidant and hormone prolactin in SCZ 
suggested that sex differences in oxidative stress may be 
related to hormone differences between males and females 
(Zhang et al. 2006). 
 Aging and age-related diseases are often associated 
with high levels of free radicals and oxidative stress. 
An elderly person would have lower antioxidant level 
and more susceptible to diseases compared to a younger 
person (Buijsse et al. 2005). In the process of brain aging, 
free radicals attack the lipid composition of brain cell 
membrane, resulting in abnormal signal transduction 
that is portrayed in symptoms of mental illness (Mazza 
et al. 2007). This trend applies in the SCZ patient group, 
but not the control group, where the oldest control group 
have higher score the youngest control group. Overall 
results suggest SCZ might contribute to the low carotenoid 
level in patients. On the other hand, analysis in duration 
of illness did not differ significantly among patients, 
thus was excluded as contributing factor of reduced 
antioxidant level. 
 Antipsychotic drugs serve to relieve schizophrenic 
symptoms but they would also produce distressing 
extrapyramidal side effects and some patients may develop 
tardive dyskinesia (Liska 2004; Parrott et al. 2004). 
Tardive dyskinesia is associated with low antioxidant 
levels in smokers, suggesting possible relationship 
between antioxidant and antipsychotic drugs (Diehl et al. 
2009). Treatments with antipsychotic drugs induce lipid 
peroxidation and oxidative stress, thus lowering antioxidant 
level (Schmidt et al. 2008). Similarly, our findings showed 
that regardless of the type of antipsychotics, patients under 
drug treatment have a significant lower antioxidant score 
compared to controls. Intramuscular depot injection allows 
direct entry of antipsychotics into the bloodstream which 
promotes immediate effect of the drug but this might also 
cause more serious side effects (Liska 2004). Our results 
indicated that carotenoid score of patients with and without 
injection were not statistically different, suggesting depot 
injection does not further increase oxidative stress in 
patients. Gender, age, and duration of illness were thus 
eliminated as factors reducing carotenoid level. 
 In conclusion, SCZ patients have significantly lower 
carotenoid level compared to healthy controls, indicating 
higher level of oxidative stress in SCZ. Antipsychotic 
treatment and SCZ illness were suggested to be the 
possible reasons to the reduction of antioxidant level in 
schizophrenic patients. The strength of this paper is the 
sample size is good and it is among one of the first research 
into measuring carotenoid level of people suffering from 
SCZ using a non-invasive method. The limitation of this 
current study is that we did not study the lifestyle and 
diet as factors reducing carotenoid level. Further study 
that includes dietary antioxidant supplement in treatment, 
ethnic and antipsychotic drug dosage may be rewarding.
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